Forskning ved Københavns Universitet - Københavns Universitet

Forside

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • Baslund, Bo
  • Niels Tvede
  • Bente Danneskiold-Samsøe
  • Per Larsson
  • Gabriel Panayi
  • Joergen Petersen
  • Lars J Petersen
  • Frank J M Beurskens
  • Janine Schuurman
  • Jan G J van de Winkel
  • Paul W H I Parren
  • J Alastair Gracie
  • Sarah Jongbloed
  • Foo Y Liew
  • Iain B McInnes
Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in rheumatoid arthritis (RA) inflammatory synovitis. Our objective was to study the ability of HuMax-IL15, a human IgG1 anti-IL-15 monoclonal antibody, to neutralize exogenous and endogenous IL-15 activity in vitro and to perform a phase I-II dose-escalation trial with HuMax-IL15 in patients with active RA.
OriginalsprogEngelsk
TidsskriftArthritis & Rheumatism
Vol/bind52
Udgave nummer9
Sider (fra-til)2686-92
Antal sider7
ISSN0004-3591
DOI
StatusUdgivet - 1 sep. 2005

ID: 34052701